Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
INDSWFTLAB •NSE
Ind-Swift Laboratories
₹329.59-3.92 (1.18%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
325.21
Today’s high
337.60
52 week low
87.15
52 week high
351.30
Open price
335.17
Previous close
333.51
Live volume
3,66,668
Lower circuit
263.68
Upper circuit
395.50
Fundamentals
Market Cap
₹2,898Cr
ROE
3.57%
P/E Ratio(TTM)
50.57
EPS(TTM)
6.59
P/B Ratio
2.09
Dividend Yield
0.00%
Industry P/E
37.23
Book Value
159.17
Debt to Equity
0.01
Face Value
10
Financial performance
JUN '26
Revenue (Cr)
₹199
+15.75%
Profit (Cr)
₹24.57
+62.61%
050100150200
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +19% |
| 3Y CAGR | -16% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | +184% |
| 3Y CAGR | +391% |
About
For over 29 years, Ind-Swift Laboratories has established itself as a prominent global pharmaceutical brand, known for its dedicated and passionate efforts in the industry. With a strong legacy and financial health, the company is well-positioned to navigate future challenges and is committed to its focus on creating substantial value. A key part of its recent strategy was to completely repay its debt, freeing itself from financial constraints to focus on innovation and strategic growth. The company is now moving up the value chain by transitioning from Active Pharmaceutical Ingredients (APIs) into the high-value business of formulations, or finished medicines. To enhance its presence in this new business area, the company is amalgamating with its group company, Ind Swift Ltd, which has decades of formulation experience. This strategic pivot is backed by strong performance, with the company's revenue scaling from ₹1,185 crore in FY23 to ₹1,273 crore in FY24.;
CEO/MD
Navrattan Munjal
Founded in
1995
NSE symbol
INDSWFTLAB
Shareholding pattern
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
PfizerPFIZER | ₹4,978.20 +58.20 (1.18%) | 22,514.29 | 30.62 | 5.36 | ||
Caplin Point LaboratoriesCAPLIPOINT | ₹2,560.80 +31.10 (1.23%) | 19,234.00 | 28.37 | 5.36 | ||
Astrazeneca Pharma IndiaASTRAZEN | ₹7,415.50 -91.50 (1.22%) | 18,760.75 | 110.6 | 21.5 | ||
Natco PharmaNATCOPHARM | ₹882.40 +4.90 (0.56%) | 15,721.37 | 13.73 | 1.7 |
Livesquawk •
Ind-Swift Labs plans to file 400+ IP dossiers by FY27.
This strategy aims to boost long-term, IP-led revenue visibility.
Livesquawk •
Ind Swift Lab forecasts revenue growth of 20–25% CAGR, targeting ₹1,200 crore by FY29.
Current revenue stands at ₹636 crore, showing ambitious expansion plans.
Livesquawk •
Ind Swift Lab's CDMO partnerships with Viatris, Manx, and Arrotex are operational.
These partnerships are projected to add ₹200–220 crore in revenue by FY27.
Livesquawk •
Ind Swift Laboratories approves sale of 10 acres in Punjab for ₹175M.
Livesquawk •
IND-SWIFT LABORATORIES Q1 EBITDA surged to ₹334M vs ₹92M YoY.
EBITDA margin improved significantly to 17.5% vs 5.8% YoY.
2026
10
Aug
Quarterly Result
Release date
28
May
Annual Result
Release date
31
Jan
Result
Release date
2025
14
Nov
Quarterly Result
Release date
13
Aug
Quarterly Result
Release date
11
Aug
Annual Result
Release date
Events calendar
View upcoming events in other stocks